Upper GI Session
AB050. SOH26AB_0042. Pancreaticobiliary disease in glucagon-like peptide-1 receptor agonist users: a case series
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are novel drugs licensed for type two diabetes mellitus and weight loss. Concerns exist regarding their association with pancreaticobiliary complications, including acute pancreatitis, calculous cholecystitis, and cholelithiasis. We aim to explore the proposed association of GLP-1 RAs and pancreaticobiliary disease.
